-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $50

Benzinga·11/20/2026 14:53:59
Listen to the news
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $53 to $50.